Atrium Therapeutics, Inc. (RNA) stock
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.64+0.16 (+2.47%)
Close on Nov 18, 2026Market cap $113.58MP/E –Yield –
Atrium Therapeutics cash
Cash and short-term investments held at the end of each period.
Atrium Therapeutics's cash was $232.07M at Sep 30, 2026. For fiscal 2025 it was $0.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $232.07M | – |
| Q2 FY2026 | Jun 30, 2026 | $263.90M | – |
| Q1 FY2026 | Mar 31, 2026 | $267.85M | – |
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
See a number that looks wrong?